The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of November 13.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 13.
Number 5: Intragovernmental organization The South Centre has released a paper that calls on regulatory bodies to approve “biological generics” rather than biosimilars.
Number 4: At the SMi Biosimilars North America 2017 conference, a Mylan executive warned that reference product sponsors may be involved in a “whisper campaign” against biosimilars.
Number 3: A recent review identified patient-, disease-, and treatment-related factors that may predict response to anti—tumor necrosis factor therapies.
Number 2: Contributor Sonia T. Oskouei breaks down the key facts that biosimilar stakeholders need to know about CMS’ recent change in biosimilar reimbursement policy.
Number 1: Two major biosimilar patent litigation cases came to a close in recent days, with the ruling Amgen v Apotex upheld in an appellate court, and with Janssen dropping its suit against biosimilar developer Samsung Bioepis.
To read all of these articles and more, visit centerforbiosimilars.com.